December 15th, 2015

Why Biogen (Nasdaq: BIIB) Stock Price – at $400 – Will Still Climb Higher

The Biogen Inc. (Nasdaq: BIIB) stock price was down about 6% this morning (Friday) after the company missed on Q1 earnings. Even with the drop, BIIB stock is still more than $400 per share. That high price tag has kept some investors away from BIIB stock. You see, it has climbed more than 667% in the last five years. But according to Money Morning experts, the BIIB stock price is not too high. This biotech stock has plenty of room for growth... To get full access to all Money Morning content, click here About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free . Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and visitors become smarter, more confident investors. Disclaimer: © 2015 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201. The post Why Biogen (Nasdaq: BIIB) Stock Price – at $400 – Will Still Climb Higher appeared first on Money Morning - We Make Investing Profitable .
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.